Close this search box.

Citryll Appoints Chief Medical Officer

PRESS RELEASE – March 21, 2021

Oss, The Netherlands, March 21, 2021 — Citryll today announced it has appointed Patrick Round as Chief Medical Officer. Patrick will provide leadership and direction to Clinical development strategy, Clinical Operations, Clinical Affairs, Clinical Sciences, Data Management/ Biometrics, and Drug Safety. Patrick will report to Helmuth van Es, CEO, and will serve on the Management Team.

Patrick Round graduated as a physician from Charing Cross Hospital Medical School in 1982. He has 30 years of experience in the pharmaceutical industry starting at Novo Nordisk and then Glaxo Wellcome. He has been Chief Medical Officer at Celltech, Cambridge Antibody Technology and Xention. Over the past 12 years he has taken the role of Chief Medical Officer at a number of biotech start-up companies across a wide range of therapeutic areas including companies Dezima and NorthSea Therapeutics.

“We warmly welcome Patrick and are pleased to have him join the Citryll team. His clinical vision and proven leadership, as well as his extensive clinical drug development experience, will strengthen our clinical development efforts and support the progress of Citryll’s development programs.”, said CEO and executive board member Helmuth van Es.
“Citryll is a leader and pioneer in the NETosis space with a first-in-class therapeutic antibody in development. I am excited to join the Citryll team and participate in development of a highly innovative asset and advance it into the clinic and beyond” said Patrick Round.

In June 2020 Citryll closed a series A fundraise of € 18,5 M/ $21 M in total with Seventure and Biogeneration Ventures as new investors and support of earlier investors BOM Brabant Ventures, Brightgene, ModiQuest, Curie capital as well as significant financial support from the Dutch Governement at Citryll is developing its antagonist of NET formation and NETs for autoimmunity and inflammatory conditions where NET biology contributes to pathology and disease progression.

About Citryll B.V.

Citryll B.V. is a private pharmaceutical company based in Oss, the Netherlands at the Pivot
Park and is dedicated to the development and commercialization of therapeutics that target
NETosis and NETs. Citryll was founded in 2015 by ModiQuest B.V., originator of the tACPA
patents, Helmuth van Es, CEO Citryll, and Renato Chirivi of ModiQuest B.V., CSO Citryll
and co-inventor of tACPA.

Contact: Helmuth van Es at,

Pivot Park Captains' Dinner

10 years ago, Pivot Park opened its doors to the world. Thanks to your commitment, support and confidence, we have been able to grow it into the successful and innovative biopharmaceutical campus it is today.

Now it’s time to celebrate!

We are therefore delighted to invite you – along with all your fellow CEOs at Pivot Park – to a special night out featuring inspiring art, a wonderful dinner and lots of opportunities to network and exchange ideas.

Erwin Wurm | Am I a House?

For the first time, the artist shows a cross-section of his work, from Narrow Furniture to One Minute Sculptures, within the walls of a historic building. Villa Constance, a former home that today houses Museum Jan Cunen, is not only a location but also part of the conversation. Because what exactly is a house?


The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.

Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.

This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.

We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.

Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.